Uveal Melanoma Market Size to Reach USD 1,656.7 million in 2032

(MENAFN- Navistrat Analytics) September 22, 2025- The rising incidence of eye cancers is a significant factor driving revenue growth in the uveal melanoma market. According to the American Cancer Society, in 2025, the United States is expected to see around 3,140 new cases of primary eye cancer (mostly melanomas) of the eye and orbit (1,620 among men and 1,520 among women), along with approximately 490 deaths (270 men and 220 women). Melanoma is the most common type of eye and orbital cancer in adults and occurs more frequently in white individuals compared to black individuals.

In March 2025, IDEAYA Biosciences, Inc., a precision oncology company focused on developing targeted therapies, announced that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy Designation (BTD) to darovasertib, a potential first-in-class protein kinase C (PKC) inhibitor. This designation applies to its use as a neoadjuvant treatment for adult patients with primary uveal melanoma (UM) for whom enucleation has been advised.

Uveal melanoma (UM), the most common primary intraocular cancer in adults, poses a therapeutic challenge due to its high likelihood of liver metastasis and limited response to conventional treatments. Although immunotherapy has advanced in oncology, progress in addressing metastatic uveal melanoma (mUM) has been limited, and there is still no globally recognized standard of care.

Segments market overview and growth Insights
Based on the therapy, the uveal melanoma market is segmented into radiation, laser therapy, immunotherapy, chemotherapy, surgical treatment, and others. Radiation segment contributed the largest share in 2024. Uveal melanoma is the most prevalent primary malignant intraocular tumor in adults. Radiation oncologists employ advanced methods to deliver high doses of radiation precisely to cancer cells while limiting exposure to nearby healthy tissue, which helps reduce side effects and improve treatment outcomes. Effective treatment approaches currently include proton beam radiotherapy, plaque brachytherapy (using isotopes such as Iodine-125, Ruthenium-106, Palladium-103, and Cesium-131), along with stereotactic radiotherapy and radiosurgery techniques such as Gamma Knife, CyberKnife, and LINAC.

Regional market overview and growth insights
North America held the largest market share in the Uveal Melanoma market in 2024. The market is being driven by rising incidence of eye cancers, coupled with the development of targeted therapies and immunotherapies, is shaping the treatment landscape. Uveal melanoma, a rare form of melanoma originating from melanocytes in the uvea, represents only about 5% of all melanoma cases in the United States. However, nearly half of patients eventually develop metastatic disease, which can be life-threatening. The condition is more commonly seen in fair-skinned individuals, with smoking identified as a risk factor, and it most frequently occurs in people in their 60s.

Competitive Landscape and Key Competitors
The Uveal Melanoma market is characterized by a fragmented structure, with many competitors holding a significant share of the market. List of major players included in the Uveal Melanoma market report are:

o Eli Lilly & Co.
o Novartis
o Bristol-Myers Squibb Company
o F. Hoffmann-La Roche Ltd
o Immunocore Holdings plc
o iOnctura
o IDEAYA Biosciences
o Aura Biosciences, Inc.
o Amgen
o Pfizer Inc.
o Delcath Systems, Inc.
o Merck
o Castle Biosciences, Inc.
o Modulation Therapeutics
o Regeneron Pharmaceuticals Inc.

Major strategic developments by leading competitors
Roche Diagnostics: In August 2025, the University of Liverpool launched the Eye Cancer Artificial Intelligence Digital Bioresource (EYE-CAN-AID), designed to enhance the early detection of rare eye tumors. The initiative showcased Roche Diagnostics technology, including an advanced high-resolution scanner for examining eye cancer cells and tissues. The VENTANA DP 600 digital pathology slide scanner will play a pivotal role in generating high-quality digital images of rare ocular cancers, supporting improved diagnostic accuracy and treatment strategies for patients.

Aura Biosciences: In November 2023, Aura Biosciences, Inc., a clinical-stage biotech company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple cancer types, announced that the U.S. Food and Drug Administration (FDA) had agreed under a Special Protocol Assessment (SPA) to the design and planned analysis of CoMpass, its global Phase 3 trial of bel-sar as a first-line treatment for adult patients with early-stage choroidal melanoma (CM).

Navistrat Analytics has segmented the Uveal Melanoma market based on type, diagnosis, therapy, route of administration, end-use, and region:

• Type Outlook (Revenue, USD Million; 2022-2032)
o Choroidal Melanoma
o Ciliary Body Melanoma
o Iris Melanoma
o Conjunctival Melanoma
o Eyelid Melanoma
o Orbital Melanoma

• Diagnosis Outlook (Revenue, USD Million; 2022-2032)
o Eye Exam
o Imaging
o Biopsy
o Others

• Therapy Outlook (Revenue, USD Million; 2022-2032)
o Radiation
o Laser Therapy
o Immunotherapy
o Chemotherapy
o Surgical Treatment
o Others

• Route of Administration Outlook (Revenue, USD Million; 2022-2032)
o Oral
o Intravenous
o Tropical
o Others

• End-Use Outlook (Revenue, USD Million; 2022-2032)
o Hospital
o Ambulatory Surgical Centers
o Cancer Treatment Centers
o Ophthalmology Clinics

• Regional Outlook (Revenue, USD Million; 2022-2032)
o North America
a. U.S.
b. Canada
c. Mexico
o Europe
a. Germany
b. France
c. U.K.
d. Italy
e. Spain
f. Benelux
g. Nordic Countries
h. Rest of Europe
o Asia Pacific
a. China
b. India
c. Japan
d. South Korea
e. Oceania
f. ASEAN Countries
g. Rest of APAC
o Latin America
a. Brazil
b. Rest of LATAM
o Middle East & Africa
a. GCC Countries
b. South Africa
c. Israel
d. Turkey
e. Rest of MEA

@Navistrat Analytics

MENAFN24092025008152017457ID1110103079